Mirae Asset Global Investments Co. Ltd. Acquires 1,117 Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)

Mirae Asset Global Investments Co. Ltd. boosted its holdings in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) by 2.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 41,527 shares of the company’s stock after purchasing an additional 1,117 shares during the quarter. Mirae Asset Global Investments Co. Ltd. owned approximately 0.05% of Deciphera Pharmaceuticals worth $670,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in DCPH. SG Americas Securities LLC boosted its stake in Deciphera Pharmaceuticals by 7.9% in the 3rd quarter. SG Americas Securities LLC now owns 165,016 shares of the company’s stock worth $2,099,000 after purchasing an additional 12,042 shares during the period. Sunesis Advisors LLC bought a new position in Deciphera Pharmaceuticals in the 3rd quarter worth approximately $1,225,000. Inspire Investing LLC boosted its stake in Deciphera Pharmaceuticals by 10.4% in the 3rd quarter. Inspire Investing LLC now owns 27,532 shares of the company’s stock worth $350,000 after purchasing an additional 2,583 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in shares of Deciphera Pharmaceuticals by 96.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,026 shares of the company’s stock valued at $26,000 after acquiring an additional 997 shares during the last quarter. Finally, Panagora Asset Management Inc. bought a new position in shares of Deciphera Pharmaceuticals during the 3rd quarter valued at approximately $1,167,000. 70.96% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on DCPH shares. JPMorgan Chase & Co. increased their target price on Deciphera Pharmaceuticals from $14.00 to $16.00 and gave the company a “neutral” rating in a research report on Wednesday, March 20th. Stifel Nicolaus increased their target price on Deciphera Pharmaceuticals from $22.00 to $23.00 and gave the company a “buy” rating in a research report on Wednesday, February 7th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, Deciphera Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.00.

Deciphera Pharmaceuticals Stock Performance

NASDAQ:DCPH opened at $14.18 on Friday. The stock’s fifty day moving average is $15.61 and its 200 day moving average is $14.28. Deciphera Pharmaceuticals, Inc. has a fifty-two week low of $9.90 and a fifty-two week high of $17.73. The firm has a market capitalization of $1.15 billion, a PE ratio of -6.19 and a beta of 0.39.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last released its quarterly earnings results on Tuesday, February 6th. The company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.58) by $0.04. Deciphera Pharmaceuticals had a negative return on equity of 49.44% and a negative net margin of 119.33%. The company had revenue of $48.30 million for the quarter, compared to analyst estimates of $45.93 million. During the same quarter in the prior year, the firm posted ($0.60) EPS. Deciphera Pharmaceuticals’s quarterly revenue was up 32.9% compared to the same quarter last year. Equities analysts forecast that Deciphera Pharmaceuticals, Inc. will post -2.16 EPS for the current year.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.